

Journal of Visualized Experiments

Isolation of Region-Specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-Cell RNA Sequencing --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE60347R2
Full Title:	Isolation of Region-Specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-Cell RNA Sequencing
Section/Category:	JoVE Neuroscience
Keywords:	microglia; isolation; Brain Region; Fluorescence-activated cell sorting; Smart-seq2; Single-cell RNA sequencing; neuroimmunology; Heterogeneity
Corresponding Author:	Qingyun Li Stanford University School of Medicine Stanford, CA UNITED STATES
Corresponding Author's Institution:	Stanford University School of Medicine
Corresponding Author E-Mail:	tristan.qingyun.li@gmail.com
Order of Authors:	Lu Zhou Qingyun Li
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Palo Alto, California, USA



STANFORD UNIVERSITY SCHOOL OF MEDICINE

STANFORD, CALIFORNIA 94305-5125

DEPARTMENT OF NEUROBIOLOGY
SHERMAN FAIRCHILD SCIENCE BUILDING
TEL: (650) 723-5966
FAX: (650) 725-3958

QINGYUN LI, PH.D.
Postdoctoral Scholar
Laboratory of Ben A. Barres
Laboratory of Tony Wyss-Coray

Department of Neurobiology
Stanford School of Medicine
Direct line: (650) 736-8561
qingyun.li@stanford.edu

RE: JoVE60347
August 12, 2019

Dear Editor,

I am pleased to submit our revised manuscript entitled, "Isolation of region-specific microglia from one adult mouse brain hemisphere for deep single-cell RNA sequencing".

We made changes according to editorial comments. We tracked the changes within the manuscript to identify all of the edits. Particularly, we added two more tables in the protocol to show certain experimental conditions.

I am looking forward to hearing back from you regarding the revision. Thank you very much!

Sincerely,

A handwritten signature in black ink that reads "Qingyun Li".

Qingyun Li, Ph.D
Postdoctoral Scholar, Stanford University School of Medicine

TITLE:

Isolation of Region-Specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-Cell RNA Sequencing

AUTHORS AND AFFILIATIONS:

Lu Zhou¹, Qingyun Li¹

¹Department of Neurobiology, Stanford University School of Medicine, Stanford, CA, USA

Email address of co-author:

Lu Zhou (lzhou2015@gmail.com)

Corresponding author:

Qingyun Li (tristan.qingyun.li@gmail.com)

KEYWORDS:

microglia, isolation, brain region, fluorescence-activated cell sorting, single-cell RNA sequencing, neuroimmunology, heterogeneity

SUMMARY:

We provide a protocol for isolation of microglia from different dissected regions of an adult mouse brain hemisphere, followed by semi-automated library preparation for deep single-cell RNA sequencing of full-length transcriptomes. This method will help to elucidate functional heterogeneity of microglia in health and disease.

ABSTRACT:

As resident macrophages in the central nervous system, microglia actively control brain development and homeostasis, and their dysfunctions may drive human diseases. Considerable advances have been made to uncover the molecular signatures of homeostatic microglia as well as alterations of their gene expression in response to environmental stimuli. With the advent and maturation of single-cell genomic methodologies, it is increasingly recognized that heterogeneous microglia may underlie the diverse roles they play in different developmental and pathological conditions. Further dissection of such heterogeneity can be achieved through efficient isolation of microglia from a given region of interest, followed by sensitive profiling of individual cells. Here, we provide a detailed protocol for the rapid isolation of microglia from different brain regions in a single adult mouse brain hemisphere. We also demonstrate how to use these sorted microglia for plate-based deep single-cell RNA sequencing. We discuss the adaptability of this method to other scenarios and provide guidelines for improving the system to accommodate large-scale studies.

INTRODUCTION:

Microglia, representing 5%–10% of all neural cells, are resident macrophages scattered throughout the central nervous system (CNS)¹. Protected behind blood-brain barrier, typical microglia in a healthy adult brain contain many fine processes that rapidly extend and retract to

45 interact with neurons and other glial cells in the parenchyma. Microglia can also adopt the
46 amoeboid morphology associated with increased phagocytic function during specific
47 developmental stages or upon immune challenges in injury and disease²⁻⁴. Recent exciting
48 discoveries have clearly demonstrated that microglia are by no means passive bystanders to
49 brain-derived or pathological signals, but play pivotal roles in controlling brain development and
50 homeostasis, for instance, by supporting neuronal survival, pruning immature synapses,
51 promoting oligodendrocyte lineage cells differentiation as well as angiogenesis¹. As more
52 functions of microglia are elucidated, the excitement is further fueled by human genetics studies,
53 which showed that many neurodegenerative disease risk genes, such as TREM2, are
54 predominantly or exclusively expressed by microglia⁵⁻⁷. Given their significance in development
55 and plausible disease-driving roles, tremendous effort has recently been put towards our
56 understanding of microglial gene regulation and function in hope of finding new therapeutic
57 targets for neurodegenerative diseases^{1,8}.

58
59 RNA sequencing (RNA-seq) allows unbiased characterization of cell type-specific gene expression,
60 which in turn guides scientists to investigate gene functions in dense cellular networks⁷. RNA-seq
61 had been mostly done on bulk samples, leading to the discovery of a homeostatic microglial gene
62 signature that distinguishes them from other neural and immune cells⁹. However, such an
63 approach could overlook molecular and functional differences among microglia, especially those
64 transiently present in development, or associated with aging and disease. Indeed, single-cell
65 RNA-seq (scRNA-seq) offers the sensitivity and resolution that have revolutionized the field by
66 revealing previously underappreciated heterogeneity of microglia in a variety of contexts^{2,3,10}. In
67 addition, due to the presence of other similar immune cells at the CNS-circulation interface,
68 scRNA-seq provides information aiding the design of new tools to separate and functionally
69 dissect these related cells with little prior knowledge^{2,11}.

70
71 A diverse array of scRNA-seq platforms have been invented, each suitable for certain
72 applications¹². In general, droplet-based methods, such as 10x Genomics, are higher in
73 throughput with (tens of) thousands of cells sequenced in each run, and they are less selective
74 for the input which may contain mixed cell populations requiring broad categorization. Plate-
75 based methods provide higher sensitivity and read depth^{13,14}, usually targeting specific
76 populations from cell sorting to reveal subtle differences or rare transcripts. Given the small
77 percentage of microglial cells, particularly those development- or disease-associated
78 subpopulations, among all CNS cell types, it is often desirable to isolate microglia from a specific
79 region of interest and obtain deep and full-length transcriptomic information in order to
80 understand their heterogeneity.

81
82 Here, we provide details on how to isolate microglia from different mouse brain regions dissected
83 from a single hemisphere, which are used for single-cell (or bulk) RNA-seq following a semi-
84 automated plate-based library preparation procedure. The other hemisphere can then be used
85 for histological validation. Streamlined from a previously published method⁹, this isolation
86 protocol aims to maximize the yield from small amount of starting materials, and meanwhile
87 maintain endogenous microglial gene expression profiles. We use fluorescence-activated cell
88 sorting (FACS) to enrich microglia (or other related immune cells of interest) into 96-well plates

and miniaturize the volumes of reagents for library preparation in order to increase throughput. We highlight this sensitive scRNA-seq platform, although other plate-based strategies may be applied. This method can be easily adapted to isolate microglia from other dissected tissues, such as injury or disease foci, and the age of the mouse can vary across almost any postnatal stages. Efficient isolation of regional microglia for single-cell transcriptomics studies will facilitate better understanding of their functions in health and disease.

PROTOCOL:

All procedures involving rodents conformed to Stanford University guidelines, which comply with national and state laws and policies. All animal procedures were approved by Stanford University's Administrative Panel on Laboratory Animal Care.

NOTE: All solution and buffer compositions are provided in **Table of Materials**.

1. Preparation on the day of cell isolation

1.1. Prepare the following reagents and chill them on ice: medium A (50 mL), magnetic-activated cell sorting (MCS) buffer (30 mL), FACS buffer (25 mL), phosphate-buffered saline (PBS; 30 mL), DNase (320 μ L), and RNase inhibitor (30 μ L).

NOTE: The volumes provided here are sufficient to isolate microglia from 4 brain regions (e.g., cortex, cerebellum, hippocampus and striatum) of a single mouse brain hemisphere. Scale up if more tissues are used.

1.2. Place four clean 2 mL Dounce homogenizers on ice and add 2 mL of medium A with 80 μ L of DNase (12,500 units/mL) and 5 μ L of RNase inhibitor into each Dounce homogenizer. Chill the pistons in 15 mL tubes.

1.3. Label four 6 cm Petri dishes with brain regions for tissue collection and add 200 μ L of cold medium A into each dish on ice. Add about 5 mL of medium A into a 6 cm Petri dish for dissection.

NOTE: Prior to use, make sure all reagents are sterile and suitable for RNA applications. Bench and dissection tools need to be clean and sprayed with RNase decontamination solution (**Table of Materials**).

2. Brain region dissection

NOTE: This step should take ~30 min.

2.1. Inject 400–500 μ L of ketamine/xylazine (24 mg/mL ketamine and 2.4 mg/mL xylazine) into the peritoneum of a juvenile to adult stage mouse (>1 month old).

NOTE: A male mouse is used here for illustration, but either gender is suitable.

2.2. Wait for 5 min and pinch a hind paw to ensure lack of retraction.

2.3. Immediately use a 26 G x 3/8 needle to perform transcardial perfusion with 20–30 mL of ice-cold PBS until buffer runs out with no visible blood.

2.4. Decapitate the mouse with a pair of surgical scissors. Use small scissors to cut open the skin to expose the underneath skull, and then cut through the sagittal suture, lambdoidal suture and coronal suture. Use forceps to pull off both sides of parietal bone and interparietal bone without damaging the tissue, and carefully move the brain into the dissection Petri dish with medium A.

2.5. Use a pre-chilled blade to cut the brain through midline into two hemispheres.

NOTE: The four brain regions described here from a single hemisphere yield sufficient numbers of microglia for single-cell or bulk RNA-seq applications. The other hemisphere can be used for immunohistochemistry or RNA in situ validation.

2.6. Separate the cerebellum from the cortical lobe and the brain stem with #55 forceps and transfer the tissue into a collection Petri dish.

2.7. Use #55 forceps to carefully dissect out the hippocampus and the striatum from the cortex and transfer each tissue into a collection Petri dish.

3. Mechanical tissue dissociation

NOTE: Keep cells and reagents cool all the time except during staining steps. This step should take ~30 min.

3.1. Chop each brain tissue with a razor blade into $<1\text{ mm}^3$ fine pieces.

3.2. Use 1 mL pipette (with tips cut off) to transfer tissue pieces into the pre-chilled Dounce homogenizers, each containing 2 mL of medium A with DNase and RNase inhibitor.

3.3. Homogenize the tissue by slowly twisting the piston in and out of the Dounce homogenizer for 6–10 full strokes, until no visible chunks are present.

NOTE: Douncing kills neurons and most other glial cells but leave microglial cells rather intact. Both insufficient and over-douncing can lead to low yield of cells.

3.4. Transfer dissociated tissues into 50 mL tubes through 70 μm strainers.

3.5. Rinse each Dounce homogenizer and piston with a total of 6 mL of cold medium A and filter the rinsing solution through the same strainer into the corresponding tube.

3.6. Transfer the single cell suspensions (about 8 mL each) into 15 mL conical tubes and centrifuge at 400 x *g* for 5 min at 4 °C with brake = 5.

4. Myelin removal

NOTE: This step should take ~60 min.

4.1. Prepare 1 large depletion (LD) column (for cortex) and 3 large selection (LS) columns (for the other 3 regions) in a magnetic separator (**Table of Materials**). Rinse each column with 3 mL of MCS buffer.

4.2. Once centrifugation is finished, pipette out and discard the supernatant without disturbing the pellet. For the cortex and cerebellum tissues, resuspend cells in 850 µL of MCS buffer with 1.8 µL of RNase inhibitor. For hippocampus and striatum tissues, resuspend cells in 400 µL of MCS buffer with 0.9 µL of RNase inhibitor.

NOTE: The columns (LD vs. LS) and the volume used for resuspension are optimized based on the amount of myelin present in the tissue. If other brain regions are assayed, these conditions may need to be adjusted depending on the size of the tissue and how much myelin may exist. Effectiveness of myelin removal can be estimated in step 4.9.

4.3. Add 100 µL of myelin removal beads each into cells from cortex and cerebellum and add 50 µL of myelin removal beads each into cells from hippocampus and striatum.

4.4. Gently mix the cells with beads and incubate the tubes on ice for 10 min.

4.5. Bring the volume of the tube with cortical cells to 2 mL with MCS buffer, and all others to 1 mL (i.e., add 1 mL for cortical cells; 500 µL for hippocampal and striatal cells; no need to add buffer to cerebellar cells).

4.6. Once columns are empty of rinsing buffer, place a 15 mL tube below each column. Load cortical cells (2 mL) onto the LD column, and all others (1 mL each) onto the LS columns. Immediately use 1 mL of MCS buffer each to wash the original tubes and load the solution onto the corresponding columns.

4.7. Wash the LD column once with 1 mL of MCS buffer and wash each LS column twice with 1 mL of MCS buffer each wash. Continue to collect the flow-through solution during washing.

4.8. Filter cells into round bottom FACS tubes through 35 µm strainer caps.

NOTE: Each tube should collect about 4 mL of single cell suspension depleted of myelin.

4.9. Optionally, take 10 μ L of the cell suspension and mix it with 10 μ L of 0.4% trypan blue solution. Examine the cells under a 10x bright field microscope to estimate the yield, survival rate and the level of residual myelin.

NOTE: A successful preparation should generate over 90% live cells (round in shape and excluding the blue dye) with little to no myelin debris.

4.10. Pellet cells in the FACS tubes at 400 x *g* for 5 min at 4 °C, with brake = 5. Slowly pour out supernatant and dab the edge of the tube on tissue paper. Resuspend cells in each tube with 300 μ L of FACS buffer.

NOTE: If MCS sorting is preferred, CD11b beads can be used to select microglia and other myeloid cells following myelin removal. These cells can then be used for non-plate-based scRNA-seq as well as bulk RNA-seq. The caveat of this alternative approach is that CD11b beads do not separate microglia from other related immune cells which are also positive for this antigen.

5. Staining for fluorescence-activated cell sorting

NOTE: This step should take ~40 min.

5.1. Add 5 μ L of mouse Fc receptors block reagent (**Table of Materials**) into each tube. Incubate for 5 min on ice.

5.2. Add 1 μ L of CD45-PE-Cy7 and 1 μ L of CD11b-BV421 into each tube.

NOTE: Antibodies with other conjugated fluorophores may be used. Antibodies against TMEM119, a specific marker for homeostatic microglia⁹, can also be included, but it is recommended to be used together with CD45 and CD11b, because certain microglia subpopulations may lose TMEM119 surface expression.

5.3. Incubate the tubes on a shaker for 10 min at room temperature (RT).

5.4. Add 2 mL of FACS buffer to wash.

5.5. Pellet cells at 4 °C, 400 x *g* for 5 min. Slowly pour out supernatant and dab the edge of the tube on tissue paper. Resuspend cells in each tube using 400 μ L of FACS buffer with 1 μ L of RNase inhibitor and 0.5 μ L of propidium iodide (PI, 1:1000 dilution).

6. Index FACS sorting

NOTE: This step should take ~1 h.

6.1. Following standard FACS procedure, draw gates based on scatter (excluding debris), single cells, live cells (PI negative), microglia and myeloid cells (CD45+, CD11b+).

NOTE: Typical microglial cells express CD45 at lower levels compared with other border-associated macrophages, such as perivascular and meningeal macrophages, and therefore gating on CD45 low CD11b+ should be sufficient if the focus of the research is gene expression profiles in these classical microglia^{1,2}. However, certain subsets of microglia may have higher CD45 expression and this is particularly true during development or in disease conditions. To ensure unbiased analysis of microglial gene expression, CD45 high and CD45 low immunophenotypes can be recorded through index sorting setting and both populations collected for sequencing and downstream analysis. In addition, TMEM119 surface expression may be used to target the homeostatic microglial population (see step 5.2) and analyzed together with CD45 levels and the sequencing results.

6.2. Sort single microglia (with a 100 µm nozzle) into 96-well polymerase chain reaction (PCR) plates, containing 4 µL of lysis buffer each well (see the published protocol¹⁴ for details).

NOTE: The External RNA Control Consortium (ERCC) RNA spike-in mix (**Table of Materials**) can be added at $1:2.4 \times 10^7$ in the lysis buffer for quality control and normalization purposes².

6.3. Briefly vortex the plates and spin down using a bench-top centrifuge.

6.4. Immediately freeze the samples on dry ice. Store the plates at -80 °C until library preparation.

NOTE: Alternatively, more cells can be collected into 1.5 mL tubes with RNA extraction buffer for bulk RNA-seq. According to authors' experience, 3,000 cells are sufficient to generate good quality libraries following the published protocol^{2,14}.

7. Single-cell RNA-sequencing library preparation

NOTE: Here, the published protocol¹⁴ is followed to generate scRNA-seq libraries with the aid of liquid handling robotics and a few modifications. In this article, the procedure is only briefly described, and the differences are highlighted. Processing 4 plates simultaneously takes about 2.5 days.

7.1. Thaw plates on ice and perform reverse transcription with oligo-dT30VN primer (in the lysis buffer) to generate cDNA with thermal cyclers (**Table 1**): 42 °C 90 min; 70 °C 5 min; 4 °C hold. Then amplify cDNA with an additional exonuclease digestion step at the beginning (**Table 2**) using the PCR master mix and in situ PCR (ISPCR) primers (**Table of Materials**) and the following PCR condition: 37 °C 30 min; 95 °C 3 min; 23 cycles of 98 °C 20 s, 67 °C 15 s, 72 °C 4 min; 72 °C 5 min.

7.2. Purify cDNA using 18 µL of magnetic beads per well (0.7:1 ratio). Incubate the plate on a magnetic stand for 5 min and wash samples twice with freshly made 80% ethanol, 80 µL per well each time. After drying the plate for 15-20 min, elute cDNA with 20 µL of elution buffer per well.

NOTE: For quality control, use a fragment analyzer (high sensitivity next-generation sequencing [NGS] fragment analysis, 1–6,000 bp) to check size distributions and concentrations of cDNA, and only further process samples with a smear between 500–5,000 bp, and higher than 0.05 ng/μL.

7.3. To generate libraries, mix 0.4 μL of each cDNA sample with 1.2 μL of Tn5 tagmentation reagents from the library preparation kit (**Table of Materials**) in a 384-well plate with the aid of a nanoliter pipetting machine, at 55 °C 10 min.

NOTE: Here, 1/12.5 of the suggested reaction volume (5 μL sample and 15 μL of tagmentation reagents) is added in order to reduce cost and meanwhile increase throughput. A nanoliter pipetting machine (**Table of Materials**) is used to transfer reagents (this and following steps) from and to 384-well plates.

7.4. Add 0.4 μL of neutralization buffer to stop the tagmentation reaction at RT for 5 min.

7.5. Add 384 indexes (**Table of Materials**, 0.4 μL forward and 0.4 μL reverse), 1.2 μL of PCR mix to samples (2 μL each), and amplify the libraries using the following condition: 72 °C 3 min; 95 °C 30 s; 10 cycles of 95 °C 10 s, 55 °C 30 s, 72 °C 1 min; 72 °C 5 min.

7.6. Pool all individual libraries (take 1 μL each) from the same 384-well plate together, and use magnetic beads (**Table of Materials**, 0.7:1 ratio) to purify the final pooled libraries.

7.7. Use a fluorometer (**Table of Materials**) to measure the concentrations and a bioanalyzer (**Table of Materials**) to examine the size distributions of pooled libraries before sequencing. Target the sequencing depth at 1 million raw reads per cell.

7.8. Follow standard bioinformatic procedures to filter and trim sequencing reads and perform alignment². Use the count table and meta data as inputs to do clustering analysis with the Seurat package¹⁵.

REPRESENTATIVE RESULTS:

This protocol describes a method to isolate and sort microglia from different brain regions in one adult perfused brain hemisphere, followed by scRNA-seq. We use douncing to create single cell suspension and also as a first step to enrich microglia. Insufficient or over-douncing reduces the yield. In addition, adult mouse brains contain high levels of myelin, which can also reduce sorting efficiency and yield if not removed properly. Therefore, we examine the cell suspension under microscope by using trypan blue and a hemocytometer to estimate the yield, cell viability and efficacy of myelin removal (step 4.9) before performing antibody staining (**Figure 1**). Total cell counts at this point should be over 30,000 for cortex, and over 5,000 for other tissues. Over 90% of cells should be viable with little myelin debris.

We use a FACS machine to sort microglia (or myeloid cells), which are typically CD45 low and CD11b positive. At least for the cortical tissue, successful isolation should generate over 80% microglia out of all live single cells (**Figure 2**). The dying/dead population represents only a small

fraction of the preparation (around 10%).

Once individual microglia are captured into the lysis buffer, RNA is released and subsequently reverse transcribed to cDNA, which is then amplified for 23 cycles. It is important to check the quality of these cDNA samples—at least a portion of them—before making libraries. As a capillary electrophoresis platform, the fragment analyzer and high-sensitive NGS fragment kits (1–6,000 bp) provide quick and accurate information about size distribution as well as quantity of cDNA molecules present in each well of a 96-well plate (**Figure 3A**). Samples showing a smear (500–5,000 bp) and above certain concentration threshold (e.g., 0.05 ng/μL) can be used to make libraries. Similarly, the pooled libraries should be tested on a bioanalyzer before sequencing (**Figure 3B**).

We sequence the samples to a depth of over 1 million raw reads per cell, which saturates the detection power of this scRNA-seq methodology¹⁶. With about 60% mapping rate, over 2,000 genes per microglial cell can be detected. We obtained published data that were generated using this isolation method¹⁷, and demonstrate its reproducibility from independent experiments and sensitivity for detecting microglia-specific genes across the sequenced population (**Figure 4**).

FIGURE AND TABLE LEGENDS:

Figure 1: Estimation of microglia isolation yield, cell viability and efficiency of myelin removal.

The left panel showed the bright field image (4x magnification) of trypan blue stained cells (from cortex) after passing through myelin removal columns. Results for other regions would look similar but with fewer cells. The vast majority (if not all) of cells appeared bright (non-stained) and round due to loss of processes. The right image was the zoom-in (20x) of the boxed area and little myelin debris was present.

Figure 2: Gates used for sorting microglia. Data showed the gating strategy for sorting microglia from the cortex, and the same strategy was used for other regions. Cell debris was first excluded from the scatter plot, and single cells were gated by forward scatter-area (FSC-A)/forward scatter-width (FSC-W). Live cells were gated by PI negative staining, which were from about 90% of all single cells. Microglia, representing roughly 80% of live cells, were sorted from the CD45 low CD11b+ gate. A total of ~30,000 microglia could be isolated and sorted from the cortex tissue (from one hemisphere of a 3-month old mouse). Index sorting was performed on a FACS machine.

Figure 3: Representative quality control results for amplified cDNA from a single microglial cell and an eventual pooled library. (A) Using a fragment analyzer, all fragments are plotted with their sizes on the X axis, and relative fluorescence intensity on the Y axis, signifying the abundance of a given sized cDNA. LM (lower marker, 1 bp) and UM (upper marker, 6,000 bp) are loading markers with known concentrations used for measuring cDNA quantity. Successfully amplified cDNA from a representative microglial cell forms a curve (green dotted line) on the size distribution graph or a smear (labeled bracket) on the gel graph between 500 bp and 5,000 bp. Other labeled peaks were amplified from ERCC spike-in molecules or ribosomal RNA. The concentration of cDNA between 500 bp and 5,000 bp can be quantified, and those samples with

concentrations higher than 0.05 ng/μL and showing such typical curves are retained for library preparation. RFU, relative fluorescence unit. (B) Representative quality control result on a bioanalyzer showing size distribution of a final pooled library (with about 380 cells). Typically, it ranges from 200 bp to 2,000 bp with an average size of 400–600 bp. The two sharp peaks were loading markers. FU, fluorescence unit.

Figure 4: scRNA-seq analysis of microglia isolated from 4 brain regions of two male mice.

(A) tSNE plot showing intermingled pattern of regional microglia (only cells from mouse #1 were highlighted). They do not form distinct clusters according to region origins beyond subtle shift into concentrated areas on the tSNE plot (possibly due to batch effects). This observation is consistent with limited regional heterogeneity of microglia based on global gene expression in the adult mice (see a recent publication² for further discussion on this topic). (B) tSNE plot showing overlapping pattern of microglia from two individual mice that were processed independently. Although small batch effects may exist (cells concentrating in certain areas of the plot), these cells do not form distinct clusters according to animal origins. This result suggests the reproducibility of the protocol for comparing data between experiments. (C) Expression of microglia signature genes detected by scRNA-seq showing over 95% detection rate for specific markers, such as *Tmem119* and *P2ry12*, and over 80% detection rate for known transcription factors such as *Sall1* and *Pu.1*. The data were re-analyzed from published literature¹⁷. (D) Vast majority of isolated microglia lack expression of genes specific to other cell types, such as *Tubb3* (neurons), *Aldh1l1* (astrocytes), *Gjb1* (oligodendrocytes), and *Tie1* (endothelial cells). (E) Expression of genes related microglial activation or stress. Classical markers, *Tnf*, *Il1b*, *Nos2*, and *Nfkb2*, which are lowly expressed, are shown on the top. Early response genes, *Egr1* and *Fos*, are shown at the bottom (see discussion).

Table 1: Reverse transcription condition. Reagent volumes for one reverse transcription reaction are provided.

Table 2: PCR amplification condition. Reagent volumes for one PCR amplification of cDNA from a single cell are provided.

Table 3: Comparison between plate-based and droplet-based scRNA-seq methods. In this article, the plate-based full-length scRNA-seq procedure is provided, which has the advantages of higher sensitivity, full-length sequencing and flexibility for small numbers of cells as inputs. Droplet-based methods offer the advantages of higher throughput, lower cost, easy to perform and data in unique molecular identifiers. They are complementary depending on the purpose of the experiments.

DISCUSSION:

Microglia actively interact with other cell types in the CNS, and they are very sensitive to environmental stimuli. In order to minimize inflammatory responses and aberrant changes in their gene expression during the isolation process, this protocol has been streamlined from a previously published method⁹, and it is now suitable to isolate microglia from multiple regions of a single mouse brain hemisphere in parallel. The tissues and reagents are kept at cold

temperature and experiments are performed in a timely manner (about 3.5 h from dissection to sorting) with fewer washes and less reagents based on limited tissue sizes. We choose douncing over other homogenization methods, such as enzymatic digestion, because mechanical dissociation can kill and thus remove neurons and other glial cells while causing little damage or activation to microglia^{9,18}. Over-douncing, however, may reduce the yield of microglia and should be avoided. It has been previously shown that mechanical dissociation and beads-based myelin removal followed by FACS sorting introduce less activation to microglia, based on minimal expression of classical inflammatory genes, e.g., *Tnf*, *Il1b*, *Nos2*, and *Nfkb2*⁹ (**Figure 4E**). Nonetheless, microglia could still respond to the ex vivo conditions during dissociation and sorting by upregulating early response genes such as *Fos* and *Egr1* (**Figure 4E**), which are not normally expressed by microglia in vivo^{2,19}, and such changes from transcriptomic studies should always be validated on histology sections.

Here we provide procedures for isolating microglia from cortex, cerebellum, hippocampus and striatum from an adult mouse brain hemisphere, and this protocol can be easily adapted to other regions or stages. This is useful for situations, for example, when disease-affected microglia are limited to certain areas of the brain which can be dissected out, or in aging studies, where pooling samples is inappropriate due to significant individual variations. With the availability of antibodies against microglial (or pan innate immune) epitopes, this protocol could also be adapted for isolating microglia in rat or human tissues⁹. When adjusting for larger or older tissues, it is important to consider and test the volume of myelin-removal beads and the type of columns used. An alternative approach for myelin removal is by density gradient centrifugation in commercial low-viscosity media²⁰. Overall these two methods are comparable in their efficiency, although the density gradient centrifugation method may provide slightly higher yields, and on the other hand, the magnetic beads method is less likely to introduce endotoxins, which may activate microglia^{21,22}.

Due to the small percentage of microglia among total brain cells, it is often essential to enrich or purify microglia before performing single-cell transcriptomic studies. We use FACS as a sensitive approach to capture lowly represented cell types, and select microglia based on CD11b and CD45 surface expression. From one hemisphere, we routinely obtain ~30,000 microglia for cortex, and ~5,000 microglia for cerebellum, hippocampus or striatum. These yields are sufficient for most single-cell applications as well as bulk RNA-seq (3,000 or more cells can be used). It is worth mentioning that microglia may upregulate CD45 immunoreactivity during development or disease², in which case cells with both low and high levels of CD45 should be recorded and index sorted for analysis. Another option for enriching microglia is to use CD11b beads-mediated magnetic-activated cell sorting following myelin removal, but this would limit scRNA-seq to droplet methods.

To study microglial gene expression at single-cell resolution, we usually sort cells into at least 2–3 96-well plates per sample and perform library preparation with liquid handling machines. It has been shown that this plate-based full-length library preparation approach is one of the most sensitive scRNA-seq methods in detection limit, allowing accurate quantification of rare transcripts, such as transcription factors^{13,14,16}. Because of full-length sequencing, this approach

is not subject to 5' or 3' bias and can be used to analyze splicing variants (**Table 3**). In addition, unlike droplet-based methods, which usually require hundreds or thousands of cells in a reaction, this plate-based protocol has the flexibility to include a small number of cells in each experiment, and gradually expand the population size by adding more plates into the design later on. This is advantageous when studying small subsets of microglia in certain conditions such as embryonic development.

While this protocol reproducibly generates high-quality scRNA-seq libraries for brain regional microglia, it is often only suitable for small-scale studies due to the relatively high cost (about \$5/cell for library preparation, still cheaper than \$23/cell if using the off the shelf SmartSeq v4 kit). Several strategies can help reduce the cost and increase the throughput. First, cells can be sorted into 384-well plates with as little as 0.5 μ L of lysis buffer, and this only requires 1/8 volumes of reagents for the initial reverse transcription and PCR amplification steps. Second, it is possible to produce in-house Tn5 transposase that has similar quality as the one in a commercially available kit²³. These two modifications could reduce the library preparation cost down to \$1/cell. Third, using customized indexes, thousands of cells can be pooled together for sequencing on a system without sacrificing the sequencing depth (>1 million reads/cell)¹⁷. These improvements along with the incorporation of automated liquid handling robots, will enable high-throughput deep scRNA-seq of microglia isolated from almost any defined regions.

ACKNOWLEDGMENTS:

We thank Mariko L. Bennett, Liana Nicole Bonanno, and Spyros Darmanis for their help during the development of this protocol. This work is funded by the JPB Foundation and Vincent J. Coates Foundation.

DISCLOSURES:

The authors have nothing to disclose.

REFERENCES:

1. Li, Q., Barres, B. A. Microglia and macrophages in brain homeostasis and disease. *Nature Reviews Immunology*. **18** (4), 225-242 (2018).
2. Li, Q. et al. Developmental Heterogeneity of Microglia and Brain Myeloid Cells Revealed by Deep Single-Cell RNA Sequencing. *Neuron*. **101** (2), 207-223 (2019).
3. Keren-Shaul, H. et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell*. **169** (7), 1276-1290 (2017).
4. Bohlen, C. J. et al. Diverse Requirements for Microglial Survival, Specification, and Function Revealed by Defined-Medium Cultures. *Neuron*. **94** (4), 759-773 (2017).
5. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. *New England Journal of Medicine*. **368** (2), 117-127 (2013).
6. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer's disease. *New England Journal of Medicine*. **368** (2), 107-116 (2013).
7. Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *Journal of Neuroscience*. **34** (36), 11929-11947 (2014).
8. Colonna, M., Butovsky, O. Microglia Function in the Central Nervous System During Health and

- Neurodegeneration. *Annual Review of Immunology*. **35**, 441-468 (2017).
9. Bennett, M. L. et al. New tools for studying microglia in the mouse and human CNS. *Proceedings of the National Academy of Sciences of the United States of America*. **113** (12), 1738-1746 (2016).
10. Hammond, T. R. et al. Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes. *Immunity*. **50** (1), 253-271 (2019).
11. Van Hove, H. et al. A single-cell atlas of mouse brain macrophages reveals unique transcriptional identities shaped by ontogeny and tissue environment. *Nature Neuroscience*. **22** (6), 1021-1035 (2019).
12. Chen, G., Ning, B., Shi, T. Single-Cell RNA-Seq Technologies and Related Computational Data Analysis. *Frontiers in Genetics*. **10**, 317, (2019).
13. Svensson, V. et al. Power analysis of single-cell RNA-sequencing experiments. *Nature Methods*. **14** (4), 381-387 (2017).
14. Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. *Nature Protocols*. **9** (1), 171-181 (2014).
15. Macosko, E. Z. et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell*. **161** (5), 1202-1214 (2015).
16. Ziegenhain, C. et al. Comparative Analysis of Single-Cell RNA Sequencing Methods. *Molecular Cell*. **65** (4), 631-643 (2017).
17. Tabula Muris, C. et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. *Nature*. **562** (7727), 367-372 (2018).
18. Bohlen, C. J., Bennett, F. C., Bennett, M. L. Isolation and Culture of Microglia. *Current Protocols in Immunology*. **125** (1), e70 (2018).
19. Haimon, Z. et al. Re-evaluating microglia expression profiles using RiboTag and cell isolation strategies. *Nature Immunology*. **19** (6), 636-644 (2018).
20. Collins, H. Y., Bohlen, C. J. Isolation and Culture of Rodent Microglia to Promote a Dynamic Ramified Morphology in Serum-free Medium. *Journal of Visualized Experiments*. (133), e57122 (2018).
21. Nikodemova, M., Watters, J. J. Efficient isolation of live microglia with preserved phenotypes from adult mouse brain. *Journal of Neuroinflammation*. **9**, 147 (2012).
22. Swartzlander, D. B. et al. Concurrent cell type-specific isolation and profiling of mouse brains in inflammation and Alzheimer's disease. *Journal of Clinical Investigation Insight*. **3** (13), 121109 (2018).
23. Hennig, B. P. et al. Large-Scale Low-Cost NGS Library Preparation Using a Robust Tn5 Purification and Tagmentation Protocol. *G3 (Bethesda)*. **8** (1), 79-89 (2018).







Figure2







Reagent	Volume (μL)
Cell lysis	4
Reverse transcriptase (100 U/μL)	0.95
Rnase inhibitor	0.25
5x First strand buffer	2
Dithiothreitol (DTT; 100 mM)	0.5
Betaine (5 M)	2
MgCl ₂ (1 M)	0.06
Template switch oligo (TSO; 100 μM)	0.1
H ₂ O	0.14
Total	10

Reagent	Volume (μL)
Reverse transcription product	10
2x PCR master mix	12.5
ISPCR primer (10 μM)	0.25
Lambda exonuclease	0.1125
H ₂ O	2.1375
Total	25

Sensitivity
Full length
Flexibility for cell numbers/populations
Throughput
Unique molecular identifier
Cost per cell
Experimental difficulty
Cell populations

Plate-based (this protocol)

More genes detected

Yes

Suitable for characterization of small or rare subpopulations

Up to several thousands of cells

No

\$1-\$5

More steps and usually require liquid handling robotics

Targeted by FACS sorting

Droplet-based (10x Genomics)

Fewer genes detected

No (5' or 3' end)

Suitable for broad categorization of large cell populations

Hundreds to tens of thousands of cells

Yes

less than \$1

Simple to perform with commercialized machines

Unbiased

Name of Material/ Equipment**Reagents**

5 M Betaine

10 mM dNTP mix

0.5 M EDTA, pH 8.0

10X Hanks' Balanced Salt Solution

1 M HEPES

1X KAPA HIFI Hotstart Master Mix

5 mL Round Bottom Polystyrene Tube, with Cell Strainer Cap

AATI, High Sensitivity NGS Fragment Analysis Kit (1 bp – 6,000 bp)

Bovine Serum Albumin

DNase I

DTT, Molecular Grade

ERCC RNA Spike-In Mix

Fetal Bovine Serum

Illumina XT Index Kit v2 Set A (96 indexes)

Illumina XT Index Kit v2 Set B (96 indexes)

Illumina XT Index Kit v2 Set C (96 indexes)

Illumina XT Index Kit v2 Set D (96 indexes)

Lambda Exonuclease (5 U/ μ l)

Mouse Fc block

Myelin removal beads

Nextera XT DNA Sample Prep Kit

NextSeq 500/550 High Output Kit v2.5 (150 Cycles)

PBS (10X), pH 7.4

PCRClean DX beads

Propidium Iodide

Qubit dsDNA HS Assay Kit

Rat monoclonal anti mouse/human CD11b, Brilliant Violet 421 (clone M1/70)

Rat monoclonal anti mouse CD45, PE/Cy7 (clone 30-F11)

Recombinant RNase Inhibitor

SMARTScribe Reverse Transcriptase (100 U/ μ l)

Oligonucleotides

0.1 μ M ISPCR Oligo: 5' - AAGCAGTGGTATCAACGCAGAGT-3'

Oligo-dT30VN primer: 5' - AAGCAGTGGTATCAACGCAGAGTACT 30 VN-3'

TSO 5' - AAGCAGTGGTATCAACGCAGAGTACATrGrG+G-3' ("r" is for ribobases and "+" is for a

Solutions

FACS buffer

MCS buffer

Medium A

Plates

384-well Rigi-Plate PCR Microplates, Axygen Scientific

Hard-shell 96-well PCR plates

Others

Dumont #55 forceps

Dounce homogenizer, 2 ml

LD column

LS column

MACS MultiStand

QuadroMACS Separator

RNAzap

Strainer (70 μ m)

Equipment

BD FACSAria II

Bioanalyzer

Fragment Analyzer

Mosquito HTS nanoliter pipetting robot

Qubit 4 Fluorometer

Company**Catalog Number**

Sigma-Aldrich Cat# B0300-5VL

Thermo Fisher Scientific Cat# R0192

Thermo Fisher Scientific Cat# 15575020

Thermo Fisher Scientific Cat# 14185-052

Thermo Fisher Scientific Cat# 15630080

Kapa Biosciences Cat# KK2602

Corning Cat# 352235

Advanced Analytical Cat# DNF-474-1000

Sigma Aldrich Cat# A8806

Worthington Cat# LS002007

Promega Cat# P1171

Thermo Fisher Scientific Cat# 4456740

Thermo Fisher Scientific Cat# 10437-028

Illumina Cat# FC-131-2001

Illumina Cat# FC-131-2002

Illumina Cat# FC-131-2003

Illumina Cat# FC-131-2004

New England BioLabs Cat# M0262S

BD Pharmingen Cat# 553142

Miltenyl Biotec Cat# 130-096-433

Illumina Cat# FC-131-1096

Illumina Cat# 20024907

Thermo Fisher Scientific Cat# 70011044

Aline Biosciences Cat# C-1003-50

Thermo Fisher Scientific Cat# P3566

Thermo Fisher Scientific Cat# Q32851

BioLegend Cat# 101236; RRID: AB_11203704

Thermo Fisher Scientific Cat# 25-0451-82; RRID: AB_469625

Takara Bio Cat# 2313B

Clontech Cat# 639538

n LNA base)

VWR 89005-556

Bio-Rad HSP9631

Fine Science Tools 11295-51

Wheaton 357422

Miltenyi Biotec 130-042-901

Miltenyi Biotec 130-042-401

Miltenyi Biotec 130-042-303

Miltenyi Biotec 130-090-976

ThermoFisher Scientific AM9780

Falcon 352350


BD Biosciences http://www.bdbiosciences.com/documents/BD_FACSAria_II_cell

Agilent 2100

Agilent 5300

TTP Labtech <https://www.ttplabtech.com/products/liquid-handling/mosquito-hts/>

Thermo Fisher Scientific Q33226

Comments/Description

Working solution: 12500 units/ml

Staining: 1:1000

Staining: 1:300

Staining: 1:300

Containing 5x First strand buffer

(Picelli et al., 2014)

(Picelli et al., 2014)

(Picelli et al., 2014)

Recipe: sterile-filtered 1% FBS, 2 mM EDTA, 25 mM HEPES in 1X PBS

Recipe: sterile-filtered 0.5% BSA, 2 mM EDTA in 1X PBS

Recipe: 15 mM HEPES, 0.5% glucose in 1X HBSS without phenol red

[sorter_brochure.pdf](#)



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Isolation of region-specific microglia from one adult mouse brain hemisphere for deep single-cell RNA sequencing

Author(s):

Lu Zhou and Qingyun Li

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JOVE"** means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

CORRESPONDING AUTHOR

Name:

Qingyun Li

Department:

Neurobiology

Institution:

Stanford University

Title:

Postdoctoral scholar

Signature:



Date:

May 30, 2019

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Editorial comments:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

This has been done.

2. Please use SI abbreviations for all units: L, mL, μ L, h, min, s, etc. Please use the micro symbol μ instead of u and abbreviate liters to L (L, mL, μ L) to avoid confusion.

This has been done.

3. Please include a space between all numbers and the corresponding unit: 15 mL, 5 g, 7 cm, 37 °C, 60 s, 24 h, etc.

This has been done.

4. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols ([™]), registered symbols ([®]), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials. You may use the generic term followed by “(Table of Materials)” to draw the readers’ attention to specific commercial names. Examples of commercial sounding language in your manuscript are: Falcon, QuadroMACS, Fc block, Kimwipe, PCRClean DX, Illumina, Nextera, BD FACSAria II, etc.

This has been done.

5. 2.1: Is male or female mouse used here?

This has been specified (line 127-128).

6. After you have made all the recommended changes to your protocol section, please highlight in yellow up to 2.75 pages (no less than 1 page) of protocol text (including headers and spacing) to be featured in the video. Bear in mind the goal of the protocol and highlight the critical steps to be filmed. Our scriptwriters will derive the video script directly from the highlighted text.

This has been done.

7. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted steps form a cohesive narrative with a logical flow from one highlighted step to the next. The highlighted text must include at least one action that is written in the imperative voice per step. Notes cannot usually be filmed and should be excluded from the highlighting.

This has been done.

8. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

This has been done.

9. Figure 1: Please use the micro symbol μ instead of u.

This has been done.

10. Table of Materials: Please sort the materials alphabetically by material name.

This has been done.

11. References: Please do not abbreviate journal titles; use full journal name.

This has been done.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

The manuscript by Zhou and Li details a rapid isolation of microglia by FACS and SMART-seq. The manuscript is well written and easy to follow. The authors include helpful notes to help readers adapt the protocol to their existing protocols. The technique is beneficial to the microglial community, who are increasingly interested in using single-cell RNAseq techniques to dissect cell diversity and function. There are a few points that require further clarification:

*The protocol could be improved by using a more specific microglial marker for FACS, such as TMEM119 or P2RY12. While microglia do generally express lower levels of CD45, this can change with disease, making it more difficult to distinguish microglial cells from other macrophage populations. A note regarding this point would suffice.

We agree that TMEM119 and P2RY12 can be more specific to microglia, but recent studies showed that certain microglia populations downregulate these surface markers, especially during development and disease (Li et al., Neuron. 2019; Keren-Shaul et al., Cell. 2017). In addition, some border associated macrophages in the choroid plexus are also found to express TMEM119/P2RY12 (Van Hove, Nature Neuroscience. 2019). Because microglia could lose TMEM119/P2RY12 (meanwhile upregulate CD45), using these "specific" markers alone for sorting may exclude interesting subpopulations unique to development or disease. This is the main reason we recommend using CD45 for index sorting to "catch all" (i.e. including both CD45 low and hi), although TMEM119 surface expression can be recorded as part of the meta data and analyzed together with the sequencing results in the end. We have added a couple sentences in Step 5.2 and Step 6.1 to discuss this option.

*There are other methods currently used in the field to remove myelin for microglial cell isolation (e.g. Percoll centrifugation). A discussion comparing these methods vs. the Miltenyl beads would be helpful.

Nikodemova et al. compared Percoll, Sucrose, and Myeline removal beads methods for myelin removal, and found that Percoll provides the best results in terms of viability and yield, although this advantage is marginal compared with the beads method (Nikodemova et al, 2012).

Swartzlander et al. discussed the differences between Miltenyi Myelin removal beads and Percoll, and showed in a table that Percoll or Percoll PLUS contains higher levels of endotoxins. This may artificially activate microglia (Swartzlander JCI Insight, 2018).

We have included some discussion (line 925-929) on this point, citing these two papers.

*The images in Figure 1 are not very informative. The authors should consider replacing with images where the trypan blue staining can be better appreciated.

In our hands, the vast majority of cells after myelin removal are round shaped, and appear to be microglia. These cells rarely stain blue, and therefore are live cells. Since viability is usually not an issue following our protocol, in this picture, we mainly want to show the shape, density and scale of these cells, as well as devoid of cell debris. We edited the sentence in the Figure 1 legend to make it clearer.

*In Figure 3, it would be helpful to better explain to readers less familiar with these techniques what would be the upper and lower limit of quality that will allow for interpretable results.

We edited the figure legend for Figure 3 and also added more labels on the graph to explain how to interpret these results.

*In Figure 4, the authors note that they do not see regional differences in the microglial clustering. However, there appears to be some region-specific clustering. While hippocampal microglia are dispersed throughout the tSNE, there do seem to be distinct clusters of cortical, striatal, and cerebellar microglia. Also, there is existing literature that shows region-specific differences in microglial gene expression (e.g. Ayata et al. Nat Neurosci 2018). The authors should discuss these results and how they relate to their data set.

We appreciate the reviewer pointing out this interesting observation. Although these regional microglia “appear” to concentrate on certain areas of the tSNE plot, they do not form distinct clusters according to regional origins, even with parameters of different stringencies. This is consistent with an independent scRNAseq dataset we generated and bulk RNAseq data (sorted by TMEM119), where little to none differentially expressed genes were found between regional microglia (Li et al. Neuron. 2019). It is also consistent with other published scRNA-seq datasets, where no region-specific clusters were reported (Keren-Shaul et al. Cell. 2017. Hammond et al. Immunity. 2019). We cannot exclude the possibility that these subtle variations may arise from small batch effects as cells from different tissues were processed separately.

We extensively discussed such limited regional heterogeneity in adult mice in our recently published paper (Li et al. Neuron. 2019), which was referenced here. We also discussed the comparison between our observation and Ayata’s publication in the Neuron paper. Since this manuscript is a protocol and Figure 4 just shows an example for applying the protocol, we want to focus on methodology here, and direct readers to our paper for scientific discussion (edited in line 791-794 for clarity).

*The authors state that their data are reproducible between two animals, but mouse#2 in Figure 4B largely clusters to the left and mouse#1 to the right.

Similar to the previous point, Mouse 1 and Mouse 2 do not form distinct clusters from unbiased analysis. Even though they “appear” to concentrate on certain areas of the tSNE plot, they also overlap extensively. For a multi-day experiment that includes various molecular manipulations (such as PCR amplification), and different samples were processed separately, small batch effects may be inevitable, but this does not affect clustering analysis or comparisons between experiments. We added a sentence to admit that such small batch effects may exist (line 796-798).

* It is helpful to see microglial specific genes in Figure 4C. The figure would benefit from also showing negative control genes for astrocytes, neurons, etc.

We added a panel (Figure 4D) to show these negative control genes.

*A more comprehensive discussion of the pros and cons of this technique compared to other single-cell RNAseq techniques would be very helpful and a good resource to the community. This could also be done in the form of a table.

As suggested, we added a table (Table 1) to discuss the pros and cons of plate-based (Smart-seq2) vs. droplet-based (e.g. 10X Genomics), two most commonly used scRNA-seq approaches.

*It is not clear what the authors mean in the discussion when they state on line 406-408 that “...each plate is processed individually, library preparation is not limited by the number of cells, which is advantageous when studying

small subsets of microglia in certain conditions."

We edited this sentence to make it clearer (line 979-983)

Reviewer #2:

Manuscript Summary:

The protocols manuscript by Zhou and Li describes a straightforward protocol for isolating microglia from multiple regions of the mouse brain and subsequent preparation for plate-based single-cell RNAseq. The manuscript is well written and the protocol appears straightforward to follow and seems like a great candidate for JoVE.

Major Concerns:

I have only one major comment. Does this protocol "activate" or unduly stress microglia during mechanical dissociation and douncing? Have the authors done a rigorous comparison for this issue with this protocol and other protocols that exist, that claim to stress microglia less? Also - can the authors provide some analytic or bioinformatic strategies for detecting microglial activation or stress, for example, by providing lists of marker genes that may provide some indication for stress?

This protocol is adapted and streamlined from a previously published protocol (Bennett et al., PNAS. 2016). In the earlier version, Bennett et al. had compared this approach with other published datasets to demonstrate less activation of microglia, by showing lower expression of classical inflammatory markers, such as *Tnf*, *Il1b*, *Nos2* and *Nfkb2*. We added Figure 4E to show expression of these 4 genes (upper panel) in the single cell data, and added a couple sentences in Discussion to illustrate this point (line 909-915).

We also admit that this protocol may "stress" microglia by upregulating early response genes. We showed previously by histology methods that these genes (e.g. *Egr1* and *Fos*) are not expressed by microglia *in vivo* (Li et al. Neuron. 2019). Steffen Jung group also showed that FACS sorting could artificially upregulate early response genes. We added Figure 4E (lower panel) to show their expression, and added sentences in Discussion to recommend histology validation of such gene expression.

Minor Concerns:

1. Please provide a citation in lines 53-55.

Citations added.

2. Please add a citation for ERCC RNA spike-in use and prep protocol

Citations added.

3. Is there any downside to using 1/12 the suggested reaction volume from the library prep step in 7.3?

Miniaturizing reaction volumes can dramatically cut down the cost and facilitate automation by liquid handling robotics, and with this method, well over 90% of the single cell libraries pass stringent quality controls (See Figure S1 in Li et al. Neuron. 2019). Although using smaller volumes *may* lower its detection power SMARTseq2 normally affords, this method still routinely detects at least 3 times more genes compared with other scRNA-seq methods (See Figure S5 in Tabula Muris. Nature. 2018). It is the smallest volume the used robotics can accurately pipette without sacrificing data quality.

4. Can the authors estimate the costs from this protocol? Are there considerable cost savings with this protocol compared to the off the shelf SmartSeqV4 protocol?

This protocol costs about \$5/cell for library preparation, compared with \$23/cell if using SmartSeq v4 kit. We included this information in the Discussion (line 986-988) and Table 1.

5. Please include some bioinformatics steps (or at least a link to some)

We added brief bioinformatic steps (Step 7.8) and provided citations for detailed procedures.